Abstract:Background: The Rho kinases 1 and 2 (ROCK1/2) are serine-threonine specific protein kinases that control actin cytoskeleton dynamics. They are expressed in all cells throughout the body, including cardiomyocytes, smooth muscle cells and endothelial cells, and intimately involved in cardiovascular health and disease. Pharmacological ROCK inhibition is beneficial in mouse models of hypertension, atherosclerosis, and neointimal thickening that display overactivated ROCK. However, the consequences of endothelial ROCK signaling deficiency in vivo remain unknown. To address this issue, we analyzed endothelial cell (EC) specific ROCK1 and 2 deletions. Methods: We generated Cdh5-CreERT2 driven, tamoxifen inducible loss of function alleles of ROCK1 and ROCK2 and analyzed mouse survival and vascular defects through cellular, biochemical, and molecular biology approaches. Results: We observed that postnatal or adult loss of endothelial ROCK1 and 2 was lethal within a week. Mice succumbed to multi-organ hemorrhage that occurred because of loss of vascular integrity. ECs displayed deficient cytoskeletal actin polymerization that prevented focal adhesion formation and disrupted junctional integrity. Retinal sprouting angiogenesis was also perturbed, as sprouting vessels exhibited lack of polymerized actin and defective lumen formation. In a three-dimensional endothelial sprouting assay, combined knockdown of ROCK1/2 or knockdown or ROCK2 but not ROCK1 led to reduced sprouting, lumenization and cell polarization defects caused by defective actin and altered VE-cadherin dynamics. The isoform specific role of endothelial ROCK2 correlated with ROCK2 substrate specificity for FAK and LIMK. By analyzing single and three allele mutants we show that one intact allele of ROCK2 is sufficient to maintain vascular integrity in vivo. Conclusion: Endothelial ROCK1 and 2 maintain junctional integrity and ensure proper angiogenesis and lumen formation. The presence of one allele of ROCK2 is sufficient to maintain vascular growth and integrity. These data indicate the need of careful consideration for the use of ROCK inhibitors in disease settings.

Advances in the Development of Rho-associated Protein Kinase (ROCK) Inhibitors.

ROCK inhibitor: Focus on recent updates

Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges

Discovery of Rho-kinase inhibitors by docking-based virtual screening

ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders

ROCK (RhoA/Rho Kinase) in Cardiovascular–Renal Pathophysiology: A Review of New Advancements

Discovery and Optimization of Triazine Derivatives As ROCK1 Inhibitors: Molecular Docking, Molecular Dynamics Simulations and Free Energy Calculations

Discovery Of Novel Rock1 Inhibitors Via Integrated Virtual Screening Strategy And Bioassays

Rho/Rho-associated Kinase Pathway in Glaucoma (Review).

Progress of the study of rho-kinase and future perspective of the inhibitor

ROCK inhibition in models of neurodegeneration and its potential for clinical translation

Rock the Rock of Atherosclerosis

Insight Into Rho Kinase Isoforms in Obesity and Energy Homeostasis

Small guanine nucleotide-binding protein Rho and myocardial function

Distinct Roles of ROCK1 and ROCK2 on the Cerebral Ischemia Injury and Subsequently Neurodegenerative Changes

Amelioration of albuminuria in ROCK1 knockout mice with streptozotocin-induced diabetic kidney disease.

Advances in the Development of Rho GTPase Inhibitors

Endothelial Rho kinase controls blood vessel integrity and angiogenesis

Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design

Identifying Isoononin and Candidissiol as Rho-associated protein kinase 1 (ROCK1) inhibitors: a combined virtual screening and MD simulation approach

RhoA/Rho-kinase in the Cardiovascular System